LUKE EVNIN

CIK 1134657 · Chief Executive Officer · last filed 2026-07-08

LUKE EVNIN is a Chief Executive Officer who has filed 108 SEC Form 4 insider transactions across 21 companies since 2007. The most recent filing shows the insider sold $44.7K of HOWL on Jul 8, 2026. Across all open-market trades the lifetime net is −$185.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $696.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$696.26M

Companies

21

Total Filings

108

Lifetime Open-Market Net

-$185.50M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
HOWL Director 107,429 $0.38 $41.0K -$845.3K 38 2026-07-08
TCR2 THERAPEUTICS INC. (TCRR) Delisted 10%+ Owner 3,674,978 $1.48 $5.44M -$263.8K 1 2023-05-24
Oncorus, Inc. (ONCR) Delisted Director 2,492,843 $0.12 $300.5K $2.27M 3 2022-06-24
iTeos Therapeutics, Inc. (ITOS) Delisted 10%+ Owner 3,377,687 $10.15 $34.28M -$31.71M 2 2021-09-23
TURMERIC ACQUISITION CORP. (TMPMW) Delisted Chief Executive Officer $0.00 $0 1 2021-04-30
TURMERIC ACQUISITION CORP. (TMPMU) Delisted Chief Executive Officer 415,500 $9.99 $4.15M $0 1 2020-10-20
Harpoon Therapeutics, Inc. (HARP) Delisted Director 427,595 $23.01 $9.84M $3.50M 4 2020-06-01
SNDX Director 1,138,210 $20.37 $23.19M $0 5 2018-05-25
RYTM 10%+ Owner 2,596,392 $115.48 $299.83M $10.20M 1 2017-10-11
Radius Health, Inc. (RDUS) Delisted 10%+ Owner 3,887,502 $30.00 $116.63M $0 2 2016-09-29
ARATANA THERAPEUTICS, INC. (PETX) Delisted 10%+ Owner 37,117 -$108.11M 1 2014-03-12
Epizyme, Inc. (EPZM) Delisted 10%+ Owner 2,413,819 $1.47 $3.55M -$27.30M 1 2014-02-11
ReShape Weightloss Inc. (ETRM) Delisted Director 1,397,699 $4.25M 14 2014-01-09
PCRX Director 844,566 $24.43 $20.63M -$33.62M 16 2013-06-13
MBRX Director 2,108 $0.43 $907 $168.2K 4 2009-06-25
OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted 10%+ Owner 4,222 $0 1 2009-05-29
Pharmasset Inc (VRUS) Delisted 10%+ Owner 8,591 -$24.60M 4 2008-06-24
PCS 10%+ Owner 3,080,596 $49.74 $153.23M $0 1 2007-04-26
SENORX INC (SENO) Delisted 10%+ Owner 2,242,379 $0 1 2007-04-03
CORNERSTONE THERAPEUTICS INC (CRTX) Delisted 3,853,102 $1.95 $7.51M $0 1 2007-02-15
MEMY 10%+ Owner 11,391,019 $17.50 $199.34M $20.56M 1 2007-01-05

Recent Filings

108 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-08 HOWL Sell (S) −143,199 -$44.7K EDGAR
2026-06-29 HOWL Sell (S) −157,084 -$47.1K EDGAR
2026-06-10 HOWL Sell (S) −76,928 -$28.5K EDGAR
2026-06-08 HOWL Sell (S) −105,565 -$43.0K EDGAR
2026-06-03 HOWL Sell (S) −139,803 -$63.6K EDGAR
2026-05-29 HOWL Sell (S) −141,106 -$66.2K EDGAR
2026-05-26 HOWL Sell (S) −191,762 -$86.6K EDGAR
2026-05-20 HOWL Sell (S) −171,049 -$76.4K EDGAR
2026-05-13 HOWL Sell (S) −44,679 -$24.1K EDGAR
2026-05-12 HOWL Sell (S) −407,574 -$280.2K EDGAR
Showing 110 of 108
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.